{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:36:10Z","timestamp":1794407770852,"version":"4.9.0"},"reference-count":288,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.pharmthera.2021.108053","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T11:38:21Z","timestamp":1639222701000},"page":"108053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":313,"special_numbering":"C","title":["Targeting the NLRP3 inflammasome in cardiovascular diseases"],"prefix":"10.1016","volume":"236","author":[{"given":"Stefano","family":"Toldo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Mezzaroma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo F.","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Potere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Di Nisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Biondi-Zoccai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin W.","family":"Van Tassell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Abbate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2021.108053_bb0005","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.amjcard.2014.11.003","article-title":"Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies)","volume":"115","author":"Abbate","year":"2015","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0010","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.amjcard.2009.12.059","article-title":"Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study)","volume":"105","author":"Abbate","year":"2010","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027923","article-title":"Alterations in the interleukin-1\/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse","volume":"6","author":"Abbate","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0020","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1161\/CIRCULATIONAHA.107.740233","article-title":"Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction","volume":"117","author":"Abbate","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0025","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","article-title":"Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease","volume":"126","author":"Abbate","year":"2020","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0030","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014941","article-title":"Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-segment-elevation myocardial infarction","volume":"9","author":"Abbate","year":"2020","journal-title":"Journal of the American Heart Association"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0035","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/eurjhf\/hfq017","article-title":"Interleukin-1\u03b2 modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse","volume":"12","author":"Abbate","year":"2010","journal-title":"European Journal of Heart Failure"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0040","first-page":"pvab075","article-title":"Interleukin-1 blockade with Anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials","author":"Abbate","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0045","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cvr\/cvr015","article-title":"Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy","volume":"90","author":"Abel","year":"2011","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0050","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1096\/fj.05-3718com","article-title":"Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury","volume":"19","author":"Adlam","year":"2005","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0055","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2174\/1389450118666170130145514","article-title":"TXNIP in metabolic regulation: Physiological role and therapeutic outlook","volume":"18","author":"Alhawiti","year":"2017","journal-title":"Current Drug Targets"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0060","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.3390\/molecules26123534","article-title":"Preservation of contractile reserve and diastolic function by inhibiting the NLRP3 inflammasome with OLT1177 (Dapansutrile) in a mouse model of severe ischemic cardiomyopathy due to non-reperfused anterior wall myocardial infarction","volume":"26","author":"Aliaga","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0065","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.3389\/fimmu.2018.01612","article-title":"Inflammasome priming mediated via Toll-Like receptors 2 and 4, Induces Th1-Like regulatory T cells in de novo autoimmune hepatitis","volume":"19","author":"Arterbery","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0070","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00395-018-0692-z","article-title":"Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y12 receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function","volume":"113","author":"Audia","year":"2018","journal-title":"Basic Research in Cardiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0075","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cyto.2015.05.005","article-title":"IL-1 family members in the pathogenesis and treatment of metabolic disease: Focus on adipose tissue inflammation and insulin resistance","volume":"75","author":"Ballak","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0080","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4049\/jimmunol.0901363","article-title":"Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression","volume":"183","author":"Bauernfeind","year":"2009","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0085","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jjcc.2014.10.012","article-title":"Interleukin-18-induced atherosclerosis involves CD36 and NF-\u03baB crosstalk in Apo E\u2212\/\u2212 mice","volume":"66","author":"Bhat","year":"2015","journal-title":"Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0090","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jacc.2021.02.049","article-title":"Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction","volume":"77","author":"Broch","year":"2021","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0095","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nri.2016.58","article-title":"Inflammasomes: mechanism of assembly, regulation and signalling","volume":"16","author":"Broz","year":"2016","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0100","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2016.15826","article-title":"Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial","volume":"316","author":"Brucato","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0105","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/ehjcvp\/pvx018","article-title":"Interleukin-1 blockade for the treatment of pericarditis","volume":"4","author":"Buckley","year":"2018","journal-title":"European Heart Journal - Cardiovascular Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0110","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1249\/MSS.0000000000001641","article-title":"Effects of exercise on ASC methylation and IL-1 cytokines in heart failure","volume":"50","author":"Butts","year":"2018","journal-title":"Medicine and Science in Sports and Exercise"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0115","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.cardfail.2015.12.004","article-title":"Methylation of apoptosis-associated speck-like protein with a caspase recruitment domain and outcomes in heart failure","volume":"22","author":"Butts","year":"2016","journal-title":"Journal of Cardiac Failure"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0120","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.atherosclerosis.2015.05.020","article-title":"Txnip ablation reduces vascular smooth muscle cell inflammation and ameliorates atherosclerosis in apolipoprotein E knockout mice","volume":"241","author":"Byon","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0125","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12933-014-0106-y","article-title":"Glibenclamide attenuates myocardial injury by lipopolysaccharides in streptozotocin-induced diabetic mice","volume":"13","author":"Cai","year":"2014","journal-title":"Cardiovascular Diabetology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0130","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/diabetes.51.6.1938","article-title":"Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway","volume":"51","author":"Cai","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0135","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cmet.2019.10.006","article-title":"Aging induces an Nlrp3 inflammasome-dependent expansion of adipose B cells that impairs metabolic homeostasis","volume":"30","author":"Camell","year":"2019","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102295","article-title":"SARS-CoV-2, SARS-CoV-2, and HIV-1 derived ssRNA sequences activate the NLRP3 inflammasome in human macrophages through a non-classical pathway","volume":"24","author":"Campbell","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0145","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/bloodadvances.2020003377","article-title":"Neutrophil extracellular traps and inflammasomes cooperatively promote venous thrombosis in mice","volume":"5","author":"Campos","year":"2021","journal-title":"Blood Advances"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0150","doi-asserted-by":"crossref","DOI":"10.1038\/nutd.2017.1","article-title":"Interleukin-18 mediates cardiac dysfunction induced by western diet independent of obesity and hyperglycemia in the mouse","volume":"7","author":"Carbone","year":"2017","journal-title":"Nutrition & Diabetes"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0155","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FJC.0000000000000628","article-title":"An orally available NLRP3 inflammasome inhibitor prevents western diet-induced cardiac dysfunction in mice","volume":"72","author":"Carbone","year":"2018","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0160","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jama.2021.9508","article-title":"Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: A randomized clinical trial","volume":"326","author":"Caricchio","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0165","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1074\/jbc.M117.806869","article-title":"Hydrogen sulfide inhibits NLRP3 inflammasome activation and reduces cytokine production both in vitro and in a mouse model of inflammation","volume":"293","author":"Castelblanco","year":"2018","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0170","doi-asserted-by":"crossref","first-page":"18951","DOI":"10.1073\/pnas.2009017117","article-title":"Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19","volume":"117","author":"Cauchois","year":"2020","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0175","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1016\/S2665-9913(21)00012-6","article-title":"Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study","volume":"3","author":"Cavalli","year":"2021","journal-title":"Lancet Rheumatology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0180","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00011-016-1002-6","article-title":"Activation of the TXNIP\/NLRP3 inflammasome pathway contributes to inflammation in diabetic retinopathy: a novel inhibitory effect of minocycline","volume":"66","author":"Chen","year":"2017","journal-title":"Inflammation Research"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0185","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1166\/jbn.2020.2885","article-title":"Precisely and efficiently enzyme response microspheres with immune removal escape loaded with MCC950 ameliorate cardiac dysfunction in acute myocardial infarction","volume":"16","author":"Cheng","year":"2020","journal-title":"Journal of Biomedical Nanotechnology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0190","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1093\/eurheartj\/ehz206","article-title":"Prevention of radiotherapy-induced arterial inflammation by interleukin-1 blockade","volume":"40","author":"Christersdottir","year":"2019","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0195","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1189\/jlb.0309164","article-title":"Cholesterol-dependent cytolysins induce rapid release of mature IL-1beta from murine macrophages in a NLRP3 inflammasome and cathepsin B-dependent manner","volume":"86","author":"Chu","year":"2009","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0200","doi-asserted-by":"crossref","first-page":"10366","DOI":"10.1021\/jm501072b","article-title":"Electrophilic warhead-based design of compounds preventing NLRP3 inflammasome-dependent pyroptosis","volume":"57","author":"Cocco","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0205","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/cmdc.201600055","article-title":"Design, synthesis, and evaluation of acrylamide derivatives as direct NLRP3 inflammasome inhibitors","volume":"11","author":"Cocco","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0210","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","article-title":"MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition","volume":"15","author":"Coll","year":"2019","journal-title":"Nature Chemical Biology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0215","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0220","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCRESAHA.121.318225","article-title":"Inflammation, infection and venous thromboembolism","volume":"128","author":"Colling","year":"2021","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0225","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1182\/bloodadvances.2020003918","article-title":"Heterogeneous NLRP3 inflammasome signature in circulating myeloid cells as a biomarker of COVID-19 severity","volume":"5","author":"Courjon","year":"2021","journal-title":"Blood Advances"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0230","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.redox.2015.09.005","article-title":"Reactive oxygen species and mitochondria: A nexus of cellular homeostasis","volume":"6","author":"Dan","year":"2015","journal-title":"Redox Biology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0235","doi-asserted-by":"crossref","first-page":"12504","DOI":"10.1038\/ncomms12504","article-title":"Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models","volume":"7","author":"Daniels","year":"2016","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0240","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1111\/jcmm.15127","article-title":"EU-CARDIOPROTECTION COST Action (CA16225). Mitochondrial and mitochondrial-independent pathways of myocardial cell death during ischaemia and reperfusion injury","volume":"24","author":"Davidson","year":"2020","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0245","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1161\/CIRCULATIONAHA.115.017611","article-title":"Anti-inflammatory treatment with colchicine in acute myocardial infarction: A pilot study","volume":"132","author":"Deftereos","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0250","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1136\/heartjnl-2018-313313","article-title":"Interplay of inflammation, oxidative stress and cardiovascular disease in rheumatoid arthritis","volume":"104","author":"Del Buono","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0255","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.bbi.2016.12.014","article-title":"Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-beta and cognitive function in APP\/PS1 mice","volume":"61","author":"Dempsey","year":"2017","journal-title":"Brain, Behavior, and Immunity"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0260","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12974-020-01826-0","article-title":"IC100: a nove anti-ASC monoclonal antibody improves functional outcomes in an animal model of multiple sclerosis","volume":"17","author":"Desu","year":"2020","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0265","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejim.2020.10.020","article-title":"Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19","volume":"83","author":"Di Nisio","year":"2021","journal-title":"European Journal of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0270","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1016\/S0140-6736(16)30514-1","article-title":"Deep vein thrombosis and pulmonary embolism","volume":"388","author":"Di Nisio","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0275","doi-asserted-by":"crossref","first-page":"C832","DOI":"10.1152\/ajpcell.00053.2020","article-title":"Purinergic signaling, DAMPs, and inflammation","volume":"318","author":"Di Virgilio","year":"2020","journal-title":"American Journal of Physiology. Cell Physiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0280","doi-asserted-by":"crossref","first-page":"447S","DOI":"10.1093\/ajcn\/83.2.447S","article-title":"Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process","volume":"83","author":"Dinarello","year":"2006","journal-title":"The American Journal of Clinical Nutrition"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0285","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0290","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0008-6363(03)00343-2","article-title":"Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice","volume":"59","author":"Elhage","year":"2003","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0295","doi-asserted-by":"crossref","first-page":"6973175","DOI":"10.1155\/2016\/6973175","article-title":"High glucose and lipopolysaccharide prime NLRP3 inflammasome via ROS\/TXNIP pathway in mesangial cells","volume":"2016","author":"Feng","year":"2016","journal-title":"Journal Diabetes Research"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0300","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1253\/circj.CJ-16-0949","article-title":"Colchicine improves survival, left ventricular remodeling, and chronic cardiac function after acute myocardial infarction","volume":"81","author":"Fujisue","year":"2017","journal-title":"Circulation Journal"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0305","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1021\/acs.jmedchem.8b00733","article-title":"Structural insights of benzenesulfonamide analogues as NLRP3 inflammasome inhibitors: design, synthesis, and biological characterization","volume":"61","author":"Fulp","year":"2018","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbadis.2017.10.001","article-title":"The SGK1 inhibitor EMD638683, prevents Angiotensin II-induced cardiac inflammation and fibrosis by blocking NLRP3 inflammasome activation","volume":"1864","author":"Gan","year":"2018","journal-title":"Biochimica et Biophysica Acta - Molecular Basis of Disease"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0315","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.1248\/bpb.b110679","article-title":"An exogenous hydrogen sulphide donor, NaHS, inhibits the nuclear factor kappaB inhibitor kinase\/nuclear factor kappab inhibitor\/nuclear factor-kappaB signaling pathway and exerts cardioprotective effects in a rat hemorrhagic shock model","volume":"35","author":"Gao","year":"2012","journal-title":"Biological & Pharmaceutical Bulletin"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0320","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/FJC.0000000000000667","article-title":"Nebivolol improves obesity-induced vascular remodeling by suppressing NLRP3 activation","volume":"73","author":"Gao","year":"2019","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0325","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/504761","article-title":"NADPH oxidase-induced NALP3 inflammasome activation is driven by thioredoxin-interacting protein which contributes to podocyte injury in hyperglycemia","volume":"2015","author":"Gao","year":"2015","journal-title":"Journal Diabetes Research"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.04.022","article-title":"The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction","volume":"74","author":"Gao","year":"2019","journal-title":"International Immunopharmacology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0335","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jacbts.2021.01.013","article-title":"Selective interleukin-6 trans-signaling blockade is more effective than pantantagonism in reperfused myocardial infarction","volume":"6","author":"George","year":"2021","journal-title":"Basic to Translational Science - JACC"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0340","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.4049\/jimmunol.1301974","article-title":"Inflammasome priming by lipopolysaccharide is dependent upon ERK signaling and proteasome function","volume":"192","author":"Ghonime","year":"2014","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0345","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/tri.12683","article-title":"The protective role of interleukin-18 binding protein in a murine model of cardiac ischemia\/reperfusion injury","volume":"28","author":"Gu","year":"2015","journal-title":"Transplant International"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0350","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.1073\/pnas.1620458114","article-title":"Activation of NLRP3 inflammasome complex potentiates venous thrombosis in resonse to hypoxia","volume":"114","author":"Gupta","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0355","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.redox.2018.02.013","article-title":"Reactive oxygen species promote tubular injury in diabetic nephropathy: The role of the mitochondrial ros-txnip-nlrp3 biological axis","volume":"16","author":"Han","year":"2018","journal-title":"Redox Biology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0360","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev.pathol.1.110304.100100","article-title":"Inflammation and atherosclerosis","volume":"1","author":"Hansson","year":"2006","journal-title":"Annual Review of Pathology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0365","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41385-019-0247-0","article-title":"Intestinal epithelial NAIP\/NLRC4 restricts systemic dissemination of the adapted pathogen Salmonella Typhimurium due to site-specific bacterial PAMP expression","volume":"13","author":"Hausmann","year":"2020","journal-title":"Mucosal Immunology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0370","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/nature16959","article-title":"NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux","volume":"530","author":"He","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0375","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1161\/ATVBAHA.117.309575","article-title":"NLRP3 inflammasome inhibition by MCC950 reduces atherosclerotic lesion development in apolipoprotein E-deficient mice-brief report","volume":"37","author":"van der Heijden","year":"2017","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0380","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/apha.12376","article-title":"IL-18 neutralization during alveolar hypoxia improves left ventricular diastolic function in mice","volume":"213","author":"Hillestad","year":"2015","journal-title":"Acta Physiologica (Oxford, England)"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0385","first-page":"828","article-title":"The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction","volume":"38","author":"van Hout","year":"2017","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0390","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1159\/000481846","article-title":"Protective effects of Microrna-22 against endothelial cell injury by targeting NLRP3 through suppression of the inflammasome signaling pathway in a rat model of coronary heart disease","volume":"43","author":"Huang","year":"2017","journal-title":"Cellular Physiology and Biochemistry"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0395","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.107.731877","article-title":"Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis","volume":"117","author":"Ikonomidis","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0400","first-page":"2517","article-title":"Imaging risk in multisystem inflammatory diseases","volume":"12","author":"Ikonomidis","year":"2019","journal-title":"JACC: Cardiovascular Imaging"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0405","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1161\/CIRCIMAGING.113.001193","article-title":"Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis","volume":"7","author":"Ikonomidis","year":"2014","journal-title":"Circulation. Cardiovascular Imaging"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0410","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.5551\/jat.7567","article-title":"Proatherogenic effect of interleukin-18 is exerted with high-fat diet, but not with normal diet in spontaneously hyperlipidemic mice","volume":"18","author":"Imai","year":"2011","journal-title":"Journal of Atherosclerosis and Thrombosis"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0415","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/S0140-6736(13)62709-9","article-title":"Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicenter, double-lind, placebo-controlled, randomized trial","volume":"383","author":"Imazio","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0420","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-155-7-201110040-00359","article-title":"CORP (COlchicine for Recurrent Pericarditis) Investigators. Colchicine for recurrent pericarditis (CORP): a randomized trial","volume":"155","author":"Imazio","year":"2011","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0425","author":"Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis (MAGiC-ART)"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0430","author":"Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2 (REDHART2)"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0435","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.immuni.2013.08.001","article-title":"Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation","volume":"39","author":"Iyer","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0440","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/s41416-018-0269-5","article-title":"D-dimere and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis","volume":"119","author":"Jara-Palomares","year":"2018","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0445","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/165742","article-title":"Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome","volume":"2014","author":"Ji","year":"2014","journal-title":"Mediators of Inflammation"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0450","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0455","doi-asserted-by":"crossref","first-page":"36617","DOI":"10.1074\/jbc.M112.407130","article-title":"Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation","volume":"287","author":"Juliana","year":"2012","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0460","doi-asserted-by":"crossref","first-page":"9792","DOI":"10.1074\/jbc.M109.082305","article-title":"Anti-inflammatory compounds parthenolide and Bay 11\u20137082 are direct inhibitors of the inflammasome","volume":"285","author":"Juliana","year":"2010","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0465","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/CIRCULATIONAHA.110.982777","article-title":"Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia\/reperfusion injury","volume":"123","author":"Kawaguchi","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0470","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1536\/ihj.51.348","article-title":"BAY 11\u20137082, a nuclear factor-kappaB inhibitor, reduces inflammation and apoptosis in a rat cardiac ischemia-reperfusion injury model","volume":"51","author":"Kim","year":"2010","journal-title":"International Heart Journal"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0475","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1089\/ars.2013.5309","article-title":"Production and physiological effects of hydrogen sulfide","volume":"20","author":"Kimura","year":"2014","journal-title":"Antioxidants & Redox Signaling"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0480","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000048779","article-title":"Identification and assignment of the human NIMA-related protein kinase 7 gene (NEK7) to human chromosome 1q31.3","volume":"94","author":"Kimura","year":"2001","journal-title":"Cytogenetics and Cell Genetics"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0485","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa2027892","article-title":"Phase 3 trial of Interleukin-1 trap rilonacept in recurrent pericarditis","volume":"384","author":"Klein","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0490","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/heartjnl-2020-317928","article-title":"Efficacy and safery of rilonacept for recurrent pericarditis: results from a phase II clinical trial","volume":"107","author":"Klein","year":"2020","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15548627.2015.1100356","article-title":"Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)","volume":"12","author":"Klionsky","year":"2016","journal-title":"Autophagy"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0500","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S2665-9913(20)30065-5","article-title":"Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial","volume":"2","author":"Kl\u00fcck","year":"2020","journal-title":"Lancet Rheumatology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0505","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1681\/ASN.2017080863","article-title":"Macrophage uptake of necrotic cell DNA activates the AIM2 inflammasome to regulate a proinflammatory phenotype in CKD","volume":"29","author":"Komada","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0510","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/cvr\/cvy252","article-title":"Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunxtion in salt-sensitive hypertension","volume":"115","author":"Krishnan","year":"2019","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0515","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/jce.12552","article-title":"Cardiac sarcoidosis: contemporary review","volume":"26","author":"Kron","year":"2015","journal-title":"Journal of Cardiovascular Electrophysiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0520","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.119.007582","article-title":"Inflammasome formation in granulomas in cardiac sarcoidosis","volume":"12","author":"Kron","year":"2019","journal-title":"Circulation. Arrhythmia and Electrophysiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0525","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.bbrc.2009.08.062","article-title":"Toll-like receptors and innate immunity","volume":"388","author":"Kumar","year":"2009","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0530","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10654-017-0277-4","article-title":"Serum C-reactive protein increases the risk of venous thromboembolism: a prospective study and meta-analysis of published prospective evidence","volume":"32","author":"Kunutsor","year":"2017","journal-title":"European Journal of Epidemiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0535","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0540","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1083\/jcb.200903124","article-title":"Glyburide inhibits the Cryopyrin\/Nalp3 inflammasome","volume":"187","author":"Lamkanfi","year":"2009","journal-title":"The Journal of Cell Biology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0545","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nri3452","article-title":"Activation and regulation of the inflammasomes","volume":"13","author":"Latz","year":"2013","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0550","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature11588","article-title":"The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP","volume":"492","author":"Lee","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0555","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine-Update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung","year":"2015","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0560","doi-asserted-by":"crossref","first-page":"18674","DOI":"10.1038\/s41598-020-75675-5","article-title":"IL-18 binding protein (IL-18BP) as a novel radiation countermeasure after radiation exposure in mice","volume":"10","author":"Li","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0565","doi-asserted-by":"crossref","first-page":"10845","DOI":"10.1073\/pnas.1810524115","article-title":"Cryo-EM structures of ASC and NLRC4 CARD filaments reveal a unified mechanism of nucleation and activation of caspase-1","volume":"115","author":"Li","year":"2018","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0570","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1159\/000494656","article-title":"Cathepsin B-mediated NLRP3 inflammasome formation and activation in angiotensin II -induced hypertensive mice: Role of macrophage digestion dysfunction","volume":"50","author":"Lian","year":"2018","journal-title":"Cellular Physiology and Biochemistry"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0575","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019177","article-title":"Combined therapy with polyethylene Glycol-20k and MCC950 preserves post-resuscitated myocardial function in a rat model of cardiac arrest and cardiopulmonary resuscitation","volume":"10","author":"Liang","year":"2021","journal-title":"Journal of the American Heart Association"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0580","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1161\/CIRCULATIONAHA.120.046301","article-title":"Postischemic administration of IL-1\u03b1 neutralizing antibody reduces brain damage and neurological deficit in experimental stroke","volume":"142","author":"Liberale","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0585","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3389\/fimmu.2018.00958","article-title":"Potential of murine IgG1 and human IgG4 to inhibit the classical complement and Fc\u03b3 receptor activation pathways","volume":"8","author":"Lilienthal","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0590","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.4161\/cc.24903","article-title":"Role of lysosome rupture in controlling Nlrp3 signaling and necrotic cell death","volume":"12","author":"Lima","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0595","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s12264-020-00544-0","article-title":"Macrophage-NLRP3 inflammasome activation exacerbates cardiac dysfunction after ischemic stroke in a mouse model of diabetes","volume":"36","author":"Lin","year":"2020","journal-title":"Neuroscience Bulletin"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0600","doi-asserted-by":"crossref","first-page":"13440","DOI":"10.1111\/jcmm.15969","article-title":"Calhex231 ameliorates myocardial fibrosis post myocardial infarction in rats through the autophagy-NLRP3 inflammasome pathway in macrophages","volume":"24","author":"Liu","year":"2020","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0605","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nature18629","article-title":"Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores","volume":"535","author":"Liu","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0610","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00395-014-0415-z","article-title":"TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia\/reperfusion injury","volume":"109","author":"Liu","year":"2014","journal-title":"Basic Research in Cardiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0615","doi-asserted-by":"crossref","first-page":"32145","DOI":"10.1073\/pnas.2009680117","article-title":"The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer's disease","volume":"117","author":"Lonnemann","year":"2020","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0620","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.cell.2014.02.008","article-title":"Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes","volume":"156","author":"Lu","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0625","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexcr.2005.03.032","article-title":"The HIN-200 family: more than interferon-inducible genes?","volume":"308","author":"Ludlow","year":"2005","journal-title":"Experimental Cell Research"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0630","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104771","article-title":"NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model","volume":"9","author":"Luo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0635","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1515\/cclm-2012-0600","article-title":"Association of nucleotide-binding oligomerization domain-like receptor 3 inflammasome and adverse clinical outcomes in patients with idiopathic dilated cardiomyopathy","volume":"51","author":"Luo","year":"2013","journal-title":"Clinical Chemistry and Laboratory Medicine"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0640","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s005920050081","article-title":"Glibenclamide: an old drug with a novel mechanism of action?","volume":"34","author":"Luzi","year":"1997","journal-title":"Acta Diabetologica"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0645","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1161\/01.RES.0000258450.44413.96","article-title":"Mitochondrial dysfunction in atherosclerosis","volume":"100","author":"Madamanchi","year":"2007","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0650","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/FJC.0000000000000053","article-title":"A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse","volume":"63","author":"Marchetti","year":"2014","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0655","first-page":"E1530","article-title":"OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation","volume":"115","author":"Marchetti","year":"2018","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0660","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13075-018-1664-2","article-title":"NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis","volume":"20","author":"Marchetti","year":"2018","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0665","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FJC.0000000000000247","article-title":"Pharmacologic inhibition of the NLRP3 inflammasome preserves cardiac function after ischemic and nonischemic injury in the mouse","volume":"66","author":"Marchetti","year":"2015","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0670","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nature04515","article-title":"Cryopyrin activates the inflammasome in response to toxins and ATP","volume":"440","author":"Mariathasan","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0675","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0680","doi-asserted-by":"crossref","first-page":"5271251","DOI":"10.1155\/2016\/5271251","article-title":"Pharmacological inhibition of NLRP3 inflammasome attenuates myocardial ischemia\/reperfusion injury by activation of RISK and mitochondrial pathways","volume":"2016","author":"Mastrocola","year":"2016","journal-title":"Oxidative Medicine and Cellular Longevity"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0685","first-page":"137","article-title":"The role of NLRP3 inflammasome in pericarditis: potential for therapeutic approaches","volume":"6","author":"Mauro","year":"2021","journal-title":"JACC BTS"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0690","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/FJC.0000000000000452","article-title":"Reduction of myocardial ischemia-reperfusion injury by inhibiting Interleukin-1 alpha","volume":"69","author":"Mauro","year":"2017","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0695","article-title":"Colchicine in acute myocardial infarction: \u201cteaching new tricks to an old dog\u201d","volume":"5","author":"Mauro","year":"2015","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0700","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.bbrc.2017.10.111","article-title":"shRNA interference of NLRP3 inflammasome alleviate ischemia reperfusion-induced myocardial damage through autophagy activation","volume":"494","author":"Meng","year":"2017","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0705","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2011.18","article-title":"Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome","volume":"2","author":"Menu","year":"2011","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0710","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1161\/01.RES.0000260203.55077.61","article-title":"A role for caspase-1 in heart failure","volume":"100","author":"Merkle","year":"2007","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0715","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1161\/CIRCULATIONAHA.121.056177","article-title":"Effect of colchicine on myocardial injury in acute myocardial infarction","volume":"144","author":"Mewton","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0720","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cophys.2020.09.013","article-title":"The inflammasome in heart failure","volume":"19","author":"Mezzaroma","year":"2021","journal-title":"Current Opinion in Physiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0725","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2119\/molmed.2014.00243","article-title":"Role of Interleukin-1 in radiation-induced cardiomyopathy","volume":"21","author":"Mezzaroma","year":"2015","journal-title":"Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0730","doi-asserted-by":"crossref","first-page":"19725","DOI":"10.1073\/pnas.1108586108","article-title":"The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse","volume":"108","author":"Mezzaroma","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0735","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ni.2550","article-title":"Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome","volume":"14","author":"Misawa","year":"2013","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0740","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1128\/CMR.00046-08","article-title":"Pathogen recognition and inflammatory signaling in innate immune defenses","volume":"22","author":"Mogensen","year":"2009","journal-title":"Clinical Microbiology Reviews"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0745","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nri3520","article-title":"Macrophages in atherosclerosis: a dynamic balance","volume":"13","author":"Moore","year":"2013","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0750","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/eurheartj\/ehu272","article-title":"The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study","volume":"36","author":"Morton","year":"2015","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0755","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1152\/physrev.00009.2014","article-title":"NOD-like receptors: versatile cytosolic sentinels","volume":"95","author":"Motta","year":"2015","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0760","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13075-015-0645-y","article-title":"Pattern recognition receptors as potential therapeutic targets in inflammatory rheumatic disease","volume":"17","author":"Mullen","year":"2015","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0765","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1073\/pnas.1117765109","article-title":"Critical role for calcium mobilization in activation of the NLRP3 inflammasome","volume":"109","author":"Murakami","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0770","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cmet.2015.09.024","article-title":"IL-18 production from the NLRP1 inflammasome prevents obesity and metabolic syndrome","volume":"23","author":"Murphy","year":"2016","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0775","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/heart.88.3.296","article-title":"Increased circulating interleukin-18 in patients with congestive heart failure","volume":"88","author":"Naito","year":"2002","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0780","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nm1415","article-title":"Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance","volume":"12","author":"Netea","year":"2006","journal-title":"Nature Medicine"},{"issue":"113","key":"10.1016\/j.pharmthera.2021.108053_bb0785","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood-2008-03-146720","article-title":"Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages","volume":"5","author":"Netea","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0790","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0795","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0800","author":"NIH COVID-19 Treatment Guidelines"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0805","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2119\/molmed.2014.00034","article-title":"Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure","volume":"20","author":"O\u2019Brien","year":"2014","journal-title":"Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0810","first-page":"1","article-title":"Induction of exaggerated cytokine production in human peripheral blood mononuclear cells by a recombinant SARS-CoV-2 spike glycoprotein S1 and its inhibition by dexamethasone","author":"Olajide","year":"2021","journal-title":"Inflammation"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0815","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.4049\/jimmunol.1301170","article-title":"The mitochondrial antiviral protein MAVS associates with NLRP3 and regulates its inflammasome activity","volume":"191","author":"Park","year":"2013","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0820","doi-asserted-by":"crossref","first-page":"708","DOI":"10.2174\/1389201019666180808162011","article-title":"Role of NLRP-3 inflammasome in hypertension: A potential therapeutic target","volume":"19","author":"Pasqua","year":"2018","journal-title":"Current Pharmaceutical Biotechnology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0825","doi-asserted-by":"crossref","first-page":"99740","DOI":"10.18632\/oncotarget.20763","article-title":"NLRP3-inflammasome inhibition prevents high fat and high sugar diets-induced heart damage through autophagy induction","volume":"8","author":"Pavillard","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0830","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.phrs.2018.03.018","article-title":"Cardiovascular diseases, NLRP3 inflammasome, and western dietary patterns","volume":"131","author":"Pavillard","year":"2018","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0835","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.4049\/jimmunol.1001284","article-title":"Basic calcium phosphate crystals induce monocyte\/macrophage IL-1beta secretion through the NLRP3 inflammasome in vitro","volume":"186","author":"Paz\u00e1r","year":"2011","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0840","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.molimm.2008.12.032","article-title":"Increased atherosclerotic lesions and Th17 in interleukin-18 deficient apolipoprotein E-knockout mice fed high-fat diet","volume":"47","author":"Pejnovic","year":"2009","journal-title":"Molecular Immunology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0845","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0022-3565(24)29317-4","article-title":"Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors","volume":"299","author":"Perregaux","year":"2001","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0850","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/sj.cdd.4402195","article-title":"Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration","volume":"14","author":"P\u00e9trilli","year":"2007","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0855","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1136\/heartjnl-2018-312979","article-title":"Cardiomyopathy, oxidative stress and impaired contractility in a rheumatoid arthritis mouse model","volume":"104","author":"Pironti","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0860","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1073\/pnas.041611398","article-title":"Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta","volume":"98","author":"Pomerantz","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0865","first-page":"1","article-title":"The role of IL-6 and IL-6 blockade in COVID.19","author":"Potere","year":"2021","journal-title":"Expert Review of Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0870","first-page":"1","article-title":"Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone","author":"Potere","year":"2021","journal-title":"Journal of Thrombosis and Thrombolysis"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0875","article-title":"Response to: \u2018Correspondence on \u2018Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study\u2019 by Potere et al\u2019 by Buckley","author":"Potere","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0880","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/annrheumdis-2020-218243","article-title":"Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study","volume":"89","author":"Potere","year":"2021","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0885","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ijid.2020.07.078","article-title":"Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation","volume":"100","author":"Potere","year":"2020","journal-title":"International Journal of Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0890","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s13054-020-03022-1","article-title":"Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis","volume":"24","author":"Potere","year":"2020","journal-title":"Critical Care"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0895","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.molcel.2012.11.009","article-title":"Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity","volume":"49","author":"Py","year":"2013","journal-title":"Molecular Cell"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0900","doi-asserted-by":"crossref","first-page":"9743280","DOI":"10.1155\/2017\/9743280","article-title":"NLRP3 inflammasome activation-mediated pyroptosis aggravates myocardial ischemia\/reperfusion injury in diabetic rats","volume":"2017","author":"Qiu","year":"2017","journal-title":"Oxidative Medicine and Cellular Longevity"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0905","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14044","article-title":"Targeting the NLRP3 inflammasome to reduce warm ischemic injury in donation after circulatory death heart","volume":"34","author":"Quader","year":"2020","journal-title":"Clinical Transplantation"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0910","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jss.2020.08.020","article-title":"Modulation of Interleukin-1 and -18 Mediated Injury in Donation after Circulatory Death Mouse Hearts","volume":"257","author":"Quader","year":"2021","journal-title":"The Journal of Surgical Research"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0915","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.xjtc.2021.06.018","article-title":"Novel approach to improve circulatory death donor heart function","volume":"9","author":"Quader","year":"2021","journal-title":"JTCVS Tech"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0920","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jvsv.2015.04.005","article-title":"Association between inflammation markers, anatomic extent of deep venous thrombosis, and venous symptoms after deep venous thrombosis","volume":"3","author":"Rabinovich","year":"2015","journal-title":"Journal of Vascular Surgery. Venous and Lymphatic Disorders"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0925","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1146\/annurev-nutr-071816-064836","article-title":"Fatty acids and NLRP3 inflammasome-mediated inflammation in metabolic tissues","volume":"37","author":"Ralston","year":"2017","journal-title":"Annual Review of Nutrition"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0930","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s12015-020-10010-z","article-title":"SARS-CoV-2 entry receptor ACE2 is expressed on very small CD45- precursor of hematopoietic and endothelial cells and in response to virus spike protein activates the Nlrp3 inflammasome","volume":"17","author":"Ratajczak","year":"2021","journal-title":"Stem Cell Reviews and Reports"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0935","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/ni.2237","article-title":"Regulation of inflammasome signaling","volume":"13","author":"Rathinam","year":"2012","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0940","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrendo.2017.90","article-title":"Adapting to obesity with adipose tissue inflammation","volume":"13","author":"Reilly","year":"2017","journal-title":"Nature Reviews. Endocrinology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0945","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014044","article-title":"Targeting the NLRP3 inflammasome with inhibitor MCC950 prevents aortic aneurysms and dissections in mice","volume":"9","author":"Ren","year":"2020","journal-title":"Journal of the American Heart Association"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0950","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejphar.2017.10.043","article-title":"Molecular mechanism of doxorubicin-induced cardiomyopathy - An update","volume":"818","author":"Renu","year":"2018","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0955","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0960","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): A double-blind, randomized, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0965","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0970","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.112.122556","article-title":"Effects of interleukin-1\u03b2 inhibition with cancakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial","volume":"126","author":"Ridker","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0975","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1093\/eurheartj\/ehz542","article-title":"Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1\u03b2 inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis","volume":"41","author":"Ridker","year":"2020","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0980","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","article-title":"Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease","volume":"128","author":"Ridker","year":"2021","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0985","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201707","article-title":"Inflammasomes are activated in responde to SARS-CoV-2 infection and are associated with COVID-19 severity in patients","volume":"218","author":"Rodrigues","year":"2021","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0990","doi-asserted-by":"crossref","DOI":"10.1177\/1470320320926049","article-title":"Effects of irbesartan on myocardial injury in diabetic rats: The role of NLRP3\/ASC\/Caspase-1 pathway","volume":"21","author":"Rong","year":"2020","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"key":"10.1016\/j.pharmthera.2021.108053_bb0995","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1538-7836.2009.03286.x","article-title":"Inflammation in deep vein thrombosis and the development of post-thrombotic syndrome: a prospective study","volume":"7","author":"Roumen-Klappe","year":"2009","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1000","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1161\/CIRCULATIONAHA.115.016160","article-title":"Targeting interleukin-1\u03b2 reduces leukocyte production after acute myocardial infarction","volume":"132","author":"Sager","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pharmthera.2015.04.004","article-title":"Hydrogen sulfide and cardioprotection\u2014Mechanistic insights and clinical translatability","volume":"152","author":"Salloum","year":"2015","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1010","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10557-008-6154-3","article-title":"Anakinra in experimental acute myocardial infarction--does dosage or duration of treatment matter?","volume":"23","author":"Salloum","year":"2009","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1015","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.pneurobio.2009.01.001","article-title":"Inflammation in Alzheimer\u2019s disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors","volume":"87","author":"Salminen","year":"2009","journal-title":"Progress in Neurobiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1020","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.3389\/fimmu.2019.02578","article-title":"OLT1177 (Dapansutrile), a Selective NLRP3 Inflammasome Inhibitor, Ameliorates Experimental Autoimmune Encephalomyelitis Pathogenesis","volume":"10","author":"S\u00e1nchez-Fern\u00e1ndez","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1025","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/cvr\/cvt091","article-title":"The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury","volume":"99","author":"Sandanger","year":"2013","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1030","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1089\/ars.2020.8058","article-title":"Mitochondrial reactive oxygen species and mitophagy: A complex and nuanced relationship","volume":"34","author":"Schofield","year":"2020","journal-title":"Antioxidants & Redox Signaling"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1035","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.jacc.2014.01.014","article-title":"Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction","volume":"63","author":"Seropian","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1040","doi-asserted-by":"crossref","first-page":"36321","DOI":"10.1074\/jbc.M708182200","article-title":"The caspase-1 digestome identifies the glycolysis pathway as a target during infection and septic shock","volume":"282","author":"Shao","year":"2007","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1045","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1161\/CIRCRESAHA.120.318629","article-title":"GSDMD-mediated cardiomyocyte pyroptosis promotes myocardial I\/R injury","volume":"129","author":"Shi","year":"2021","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.06.010","article-title":"Inflammasomes and autoimmune and rheumatic diseases: A comprehensive review","volume":"103","author":"Shin","year":"2019","journal-title":"Journal of Autoimmunity"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1055","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.3390\/cells8101224","article-title":"Exosome treatment enhances anti-inflammatory M2 macrophages and reduces inflammation-induced pyroptosis in doxorubicin-induced cardiomyopathy","volume":"8","author":"Singla","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1060","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.3389\/fimmu.2018.02305","article-title":"Regulation of NLRP3 Inflammasome by Phosphorylation","volume":"9","author":"Song","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1065","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1161\/CIRCULATIONAHA.118.034621","article-title":"Inflammation and NLRP3 inflammasome activation initiated in response to pressure overload by Ca2+\/calmodulin-dependent protein Kinase II \u03b4 signaling in cardiomyocytes are essential for adverse cardiac remodeling","volume":"138","author":"Suetomi","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1070","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2119\/molmed.2017.00077","article-title":"Inflammasome and autophagy regulation - a two-way street","volume":"23","author":"Sun","year":"2017","journal-title":"Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1075","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1080","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/FJC.0000000000000709","article-title":"Cell-specific roles of NLRP3 inflammasome in myocardial infarction","volume":"74","author":"Takahashi","year":"2019","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1085","first-page":"1","article-title":"NLRP3 inflammasome as a key driver of vascular disease","volume":"00","author":"Takahashi","year":"2021","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1090","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern recognition receptors and inflammation","volume":"140","author":"Takeuchi","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1095","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1100","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00281-007-0083-2","article-title":"The Nodosome: Nod1 and Nod2 control bacterial infections and inflammation","volume":"29","author":"Tattoli","year":"2007","journal-title":"Seminars in Immunopathology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1105","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114150","article-title":"Long-lived macrophage reprogramming drives spike protein-mediated inflammasome activation in COVID-19","volume":"13","author":"Theobald","year":"2021","journal-title":"EMBO Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1110","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrcardio.2017.161","article-title":"The NLRP3 inflammasome in acute myocardial infarction","volume":"15","author":"Toldo","year":"2018","journal-title":"Nature Reviews. Cardiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1115","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00011-020-01413-2","article-title":"Inflammasome formation in the lungs of patients with fatal COVID-19","volume":"70","author":"Toldo","year":"2021","journal-title":"Inflammation Research"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1161\/CIRCGENETICS.113.000381","article-title":"Induction of microRNA-21 with exogenous hydrogen sulfide attenuates myocardial ischemic and inflammatory injury in mice","volume":"7","author":"Toldo","year":"2014","journal-title":"Circulation. Cardiovascular Genetics"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058421","article-title":"Comparative cardiac toxicity of anthracyclines in vitro and in vivo in the mouse","volume":"8","author":"Toldo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1130","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/j.ijcard.2013.12.137","article-title":"Formation of the inflammasome in acute myocarditis","volume":"171","author":"Toldo","year":"2014","journal-title":"International Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1135","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ijcard.2016.02.043","article-title":"Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemia-reperfusion in the mouse","volume":"209","author":"Toldo","year":"2016","journal-title":"International Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1140","doi-asserted-by":"crossref","first-page":"H1553","DOI":"10.1152\/ajpheart.00158.2018","article-title":"Inflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury","volume":"315","author":"Toldo","year":"2018","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1145","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/FJC.0000000000000658","article-title":"The NLRP3 inflammasome inhibitor, OLT1177 (Dapansutrile), reduces infarct size and preserves contractile function after ischemia reperfusion injury in the mouse","volume":"73","author":"Toldo","year":"2019","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FJC.0000000000000106","article-title":"Interleukin-1\u03b2 blockade improves left ventricular systolic\/diastolic function and restores contractility reserve in severe ischemic cardiomyopathy in the mouse","volume":"64","author":"Toldo","year":"2014","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1155","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1089\/ars.2014.5989","article-title":"The inflammasome in myocardial injury and cardiac remodeling","volume":"22","author":"Toldo","year":"2015","journal-title":"Antioxidants & Redox Signaling"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1160","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/cvr\/cvu259","article-title":"Independent roles of the priming and the triggering of the NLRP3 inflammasome in the heart","volume":"105","author":"Toldo","year":"2015","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1165","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1113\/expphysiol.2012.069831","article-title":"Interleukin-1\u03b2 blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse","volume":"98","author":"Toldo","year":"2013","journal-title":"Experimental Physiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1170","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10557-012-6389-x","article-title":"Recombinant human interleukin-1 receptor antagonist provides cardioprotection during myocardial ischemia reperfusion in the mouse","volume":"26","author":"Toldo","year":"2012","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1175","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","article-title":"Colchicine in patients with acute coronary syndrome: The Australian COPS randomized clinical trial","volume":"142","author":"Tong","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1180","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jphs.2020.03.004","article-title":"Involvement of exchange protein directly activated by cAMP and tumor progression locus 2 in IL-1\u03b2 production in microglial cells following activation of \u03b2-adrenergic receptors","volume":"143","author":"Tozaki-Saitoh","year":"2020","journal-title":"Journal of Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1185","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.amjcard.2018.07.002","article-title":"Usefulness of canakinumab to improve exercise capacity in patients with long-term systolic heart failure and elevated C-reactive protein","volume":"122","author":"Trankle","year":"2018","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1190","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1016\/S2665-9913(20)30167-3","article-title":"Canakinumab in a subgroup of patients with COVID-19","volume":"2","author":"Ucciferri","year":"2020","journal-title":"Lancet Rheumatology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1195","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bbrc.2012.07.058","article-title":"Critical role of caspase-1 in vascular inflammation and development of atherosclerosis in Western diet-fed apolipoprotein E-deficient mice","volume":"425","author":"Usui","year":"2012","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1200","first-page":"305","article-title":"Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: A CT coronary angiography study","volume":"11","author":"Vaidya","year":"2018","journal-title":"JACC: Cardiovascular Imaging"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1205","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.amjcard.2013.08.047","article-title":"Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)","volume":"113","author":"Van Tassell","year":"2014","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033438","article-title":"Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure","volume":"7","author":"Van Tassell","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1215","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004373","article-title":"Interleukin-1 blockade in recently decompensated systolic heart failure: Results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial)","volume":"10","author":"Van Tassell","year":"2017","journal-title":"Circulation. Heart Failure"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1220","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1161\/CIRCULATIONAHA.113.003199","article-title":"Targeting interleukin-1 in heart disease","volume":"128","author":"Van Tassell","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1225","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005036","article-title":"IL-1 blockade in patients with heart failure with preserved ejection fraction","volume":"11","author":"Van Tassell","year":"2018","journal-title":"Circulation. Heart Failure"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1230","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/FJC.0b013e3181c87e53","article-title":"Interleukin-1 trap attenuates cardiac remodeling after experimental acute myocardial infarction in mice","volume":"55","author":"Van Tassell","year":"2010","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1235","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.2279","article-title":"The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance","volume":"17","author":"Vandanmagsar","year":"2011","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000354","article-title":"MCC950\/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition","volume":"17","author":"Vande Walle","year":"2019","journal-title":"PLoS Biology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1245","doi-asserted-by":"crossref","first-page":"7853","DOI":"10.1074\/jbc.M808824200","article-title":"Neutralization of interleukin-18 ameliorates ischemia\/reperfusion-induced myocardial injury","volume":"284","author":"Venkatachalam","year":"2009","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1250","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1093\/eurheartj\/ehz008","article-title":"Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis","volume":"40","author":"Vromman","year":"2019","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1255","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.bbrc.2019.05.045","article-title":"NLRP3 inhibition improves heart function in GPER knockout mice","volume":"514","author":"Wang","year":"2019","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1260","doi-asserted-by":"crossref","first-page":"H1438","DOI":"10.1152\/ajpheart.00441.2014","article-title":"Involvement of NLRP3 inflammasome in CVB3-induced viral myocarditis","volume":"307","author":"Wang","year":"2014","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006872","article-title":"Cathepsin B aggravates coxsackievirus B3-induced myocarditis through activating the inflammasome and promoting pyroptosis","volume":"14","author":"Wang","year":"2018","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000351179","article-title":"Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation","volume":"126","author":"Wang","year":"2013","journal-title":"Cardiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1275","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.248344","article-title":"Recent insights into the regulatory networks of NLRP3 inflammasome activation","volume":"133","author":"Weber","year":"2020","journal-title":"Journal of Cell Science"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1280","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/ni.2022","article-title":"Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling","volume":"12","author":"Wen","year":"2011","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1285","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s42255-021-00366-y","article-title":"Colchicine acts selectively in the liver to induce hepatokines that inhibit myeloid cell activation","volume":"3","author":"Weng","year":"2021","journal-title":"Nature Metabolism"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1290","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.jacc.2016.01.073","article-title":"Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction","volume":"67","author":"Westman","year":"2016","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1295","author":"WHO"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1300","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis","volume":"326","author":"WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1305","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.97054","article-title":"CaMKII\u03b4-mediated inflammatory gene expression and inflammasome activation in cardiomyocytes initiate inflammation and induce fibrosis","volume":"3","author":"Willeford","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1310","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/FJC.0000000000000847","article-title":"Acute effects of interleukin-1 blockade using anakinra in patients with acute pericarditis","volume":"76","author":"Wohlford","year":"2020","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1315","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/FJC.0000000000000931","article-title":"A phase IB, randomized, double-blinded, dose escalation, single center, repeat dose safety and pharmacodynamics study of the oral NLRP3 inhibitor dapansutrile in subjects with NYHA II-III systolic heart failure","volume":"77","author":"Wohlford","year":"2020","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1320","doi-asserted-by":"crossref","first-page":"5","DOI":"10.23736\/S0026-4725.19.05104-1","article-title":"COLCOT and CANTOS: piecing together the puzzle of inflammation and cardiovascular events","volume":"68","author":"Wohlford","year":"2020","journal-title":"Minerva Cardioangiologica"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1325","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.immuni.2019.04.003","article-title":"Inflammasome activation triggers blood clotting and host death through pyroptosis","volume":"50","author":"Wu","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1330","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.3892\/mmr.2013.1708","article-title":"Induction of autophagy contributes to the myocardial protection of valsartan against ischemia\u2013reperfusion injury","volume":"8","author":"Wu","year":"2013","journal-title":"Molecular Medicine Reports"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112891","article-title":"Impaired autophagy contributes to adverse cardiac remodeling in acute myocardial infarction","volume":"9","author":"Wu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1340","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/eurheartj\/ehx261","article-title":"IL-18 cleavage triggers cardiac inflammation and fibrosis upon \u03b2-adrenergic insult","volume":"39","author":"Xiao","year":"2018","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1345","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1350","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1172\/JCI124804","article-title":"ENTPD-1 disrupts inflammasome IL-1\u03b2-driven venous thrombosis","volume":"129","author":"Yadav","year":"2019","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1355","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1161\/CIRCULATIONAHA.107.746453","article-title":"Critical role of bone marrow apoptosis-associated speck-like protein, an inflammasome adaptor molecule, in neointimal formation after vascular injury in mice","volume":"117","author":"Yajima","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1360","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00041552-200503000-00010","article-title":"Thioredoxin: A multifunctional antioxidant enzyme in kidney, heart and vessels","volume":"14","author":"Yamawaki","year":"2005","journal-title":"Current Opinion in Nephrology and Hypertension"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1365","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.expneurol.2018.08.013","article-title":"Pretreatment with low-dose fimasartan ameliorates NLRP3 inflammasome-mediated neuroinflammation and brain injury after intracerebral hemorrhage","volume":"310","author":"Yang","year":"2018","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1370","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/1074248417702890","article-title":"The highly selective Caspase-1 inhibitor VX-765 provides additive protection against myocardial infarction in rat hearts when combined with a platelet inhibitor","volume":"22","author":"Yang","year":"2017","journal-title":"Journal of Cardiovascular Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1375","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.140","article-title":"The emerging role of Toll-like receptor 4 in myocardial inflammation","volume":"7","author":"Yang","year":"2016","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1380","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1161\/CIRCULATIONAHA.118.035202","article-title":"Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation","volume":"138","author":"Yao","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1385","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev-immunol-032414-112258","article-title":"Structural biology of innate immunity","volume":"33","author":"Yin","year":"2015","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1390","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/039463200902200208","article-title":"Inflammasomes are differentially expressed in cardiovascular and other tissues","volume":"22","author":"Yin","year":"2009","journal-title":"International Journal of Immunopathology and Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1395","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cmet.2013.09.010","article-title":"Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging","volume":"18","author":"Youm","year":"2013","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1400","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1253\/circj.71.703","article-title":"Level and value of interleukin-18 in patients with acute myocardial infarction undergoing primary coronary angioplasty","volume":"71","author":"Youssef","year":"2007","journal-title":"Circulation Journal"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1405","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijcard.2017.10.071","article-title":"LncRNA MALAT1 sponges miR-133 to promote NLRP3 inflammasome expression in ischemia-reperfusion injured heart","volume":"254","author":"Yu","year":"2018","journal-title":"International Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1410","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101523","article-title":"NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy","volume":"34","author":"Zeng","year":"2020","journal-title":"Redox Biology"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1415","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/jdi.13235","article-title":"Activation of autophagy inhibits nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome activation and attenuates myocardial ischemia-reperfusion injury in diabetic rats","volume":"11","author":"Zhang","year":"2020","journal-title":"Journal of Diabetes Investigation"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1420","doi-asserted-by":"crossref","first-page":"6847087","DOI":"10.1155\/2019\/6847087","article-title":"NLRP3 Inflammasome Is Involved in Calcium-Sensing Receptor-Induced Aortic Remodeling in SHRs","volume":"2019","author":"Zhang","year":"2019","journal-title":"Mediators of Inflammation"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1425","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/bloodadvances.2020003041","article-title":"Inflammasome activation promotes thrombosis through pyroptosis","volume":"5","author":"Zhang","year":"2021","journal-title":"Blood Advances"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1430","doi-asserted-by":"crossref","first-page":"14040","DOI":"10.1074\/jbc.RA120.015036","article-title":"Impaired NLRP3 inflammasome activation\/pyroptosis leads to robust inflammatory cell death via caspase-8\/RIPK3 during coronavirus infection","volume":"295","author":"Zheng","year":"2020","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1435","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41586-018-0372-z","article-title":"New mitochondrial DNA synthesis enables NLRP3 inflammasome activation","volume":"560","author":"Zhong","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.108053_bb1440","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCRESAHA.116.301135","article-title":"Danger signaling in atherosclerosis","volume":"116","author":"Zimmer","year":"2015","journal-title":"Circulation Research"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821002552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821002552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:20:57Z","timestamp":1759011657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725821002552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":288,"alternative-id":["S0163725821002552"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.108053","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the NLRP3 inflammasome in cardiovascular diseases","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.108053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108053"}}